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Summary 
Major histocompatibility complex (MHC) class  I molecules bind peptides of 8-10 residues in 
the endoplasmic reticulum (ElL)  and convey them to the cell surface for inspection by CD8- 
expressing T cells (TcDs+). Antigenic peptides are predominantly derived from a cytosolic pool 
of polypeptides. The proteolytic generation of peptides from polypeptides clearly begins in the 
cytosol, but it is uncertain whether the final proteolytic steps occur before or after peptides are 
transported into the ElL by the MHC-encoded peptide transporter (TAP). To study the trimming 
of antigenic peptides in the secretory pathway in the absence of cytosolic processing, we used 
an NH2-terminal signal sequence to target to the ER of TAP-deficient cells, "tandem" peptides 
consisting of two  defined TcDs+  determinants  arranged  from head to  tail.  We find that  in 
contrast to cytosolic proteases in TAP-expressing cells, which are able to liberate antigenic peptides 
from either end of a tandem peptide, proteases (probably aminopeptidases) present in an early 
secretory compartment preferentially liberate the COOH-terminal determinant. These findings 
demonstrate that proteolytic activities associated with antigen processing are not limited to the 
cytosol, but that they also exist in an early secretory compartment. Such secretory aminopeptidases 
may function to trim TAP-transported peptides to the optimal size for binding to class I molecules. 
ntigenic peptides are predominantly derived from cyto- 
solic or nuclear proteins (reviewed in references 1, 2), 
and they usually consist of 8-10 residues (3). Peptides of 8-15 
or more residues are transported from the cytosol into the 
endoplasmic reticulum (ELL) by the mHC-encoded TAP, acro- 
nymic for transporter-associated with antigen processing (4-8). 
Loosely assembled class I ol chains and 32 microglobulin are 
retained in the ER until peptide binding induces a confor- 
mational alteration, resulting in their release and rapid trans- 
port through the Golgi complex to the cell surface. Although 
the proteolytic generation of antigenic peptides from poly- 
peptides clearly begins in the cytosol, it is uncertain whether 
all processing events occur in the cytosol, or whether pep- 
tides can be trimmed once they have been exported into the 
secretory compartment. 
To study the proteolytic processing of antigenic peptides 
in the secretory pathway, we used the TAP-deficient cell line 
T2 (9,  10).  T2 cells present cytosolic peptides to TcDs+  at 
low or undetectable levels. The presentation defect can, how- 
ever, be bypassed by appending a hydrophobic NH~.-terminal 
signal sequence to target peptides to the ER (11). Such peptides 
are  presumably  liberated  from  their  NH2-terminal  signal 
through the action of signal peptidase.  Signal peptidase is 
intimately associated with the proteinacious channel used to 
convey signal-containing proteins to the ElL,  and it is be- 
lieved to act cotranslocationally (reviewed in reference 12). 
The dependence of peptide association with class I mole- 
cules in T2 cells on signal sequence targeting of peptides enables 
examination of proteolytic events that occur exclusively in 
the secretory pathway. We previously demonstrated that mouse 
TCDS + specific for viral peptides can lyse T2 cells coinfected 
with recombinant vaccinia viruses (rVV) expressing mouse 
class I molecules and antigenic peptides routed to the ER 
via NH2-terminal  signal sequences (13,  14).  In this paper, 
we use this system to examine the ef~ciency with which viral 
peptides are generated in the secretory pathway from rVV- 
encoded polypeptides consisting of an NH2-terminal signal 
sequence followed by "tandem peptides" composed of residues 
52-59 from vesicular stomatitis virus nucleocapsid protein 
(N)  (designated  Pl,  restricted  by  K b)  (15)  and  residues 
147-155 from influenza virus nucleoprotein (NP) (designated 
P2 restricted by K d) (16).  The biochemical nature and intra- 
cellular site of proteolytic generation of the P2 determinant 
were determined by HPLC analysis  of acid-soluble peptides 
associated with K d, as well as a form of K d retained in the 
ER by replacement of its cytosolic tail with that of adenovirus 
E3/19K  glycoprotein (17). 
Materials and Methods 
Cell Lines.  T2 cells (generously provided by P. Cresswell, Yale 
University, New Haven, CT) (9, 10) were maintained in IMDM 
supplemented with 7.5% FBS (vol/vol). L929 cells (American Type 
Culture Collection, Rockville, MD) were maintained in DMEM 
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supplemented with 7.5% FBS (vol/vol). L929 cells (American Type 
Culture Collection, Rockville, MD) were maintained in DMEM 
supplemented with 7.5% FBS. Both cell lines were grown at 37~ 
in an air/CO2 atmosphere (91%/9%). 
Mice.  6-8-wk-old BALB/cByJ and C57B1/6J mice were pur- 
chased from The Jackson Laboratory (Bar Harbor, ME). Mice were 
immunized intravenously with  107 PFU of rVV in balanced salt 
solution supplemented with 0.2%  BSA (wt/vol)  (BSS/BSA). 
Viruses.  The  influenza  virus  A/Puerto  Rico/8/34  (H1N1) 
(PR8) was grown in 10-d-old embryonated chicken eggs and used 
as infectious allantoic fluid. VSV Indiana strain was grown in baby 
hamster kidney cells and used as a cell-free supernatant, rVV were 
grown in thymidine kinase-deficient human  143B osteosarcoma 
cells. Construction of rW expressing full-length influenza NP (18), 
VSV N-protein  (19),  H-2K  b (14),  H-2K  a (14),  and ER-retained 
H-2K  a  (EC1sK a)  (17) have  been  described.  For  simplicity and 
clarity in this paper, the signal sequence of the E3/19K glycopro- 
rein of adenovirus 5, denoted as ES in our previous publications, 
has been replaced with S denoting the signal sequence￿9 In con- 
struction of rVV expressing nontargeted minigenes, an initiation 
Met (M) precedes each minigene product.  Recombinant VV ex- 
pressing  N52-s9 residues  (M-P1 and S-P1),  and  NP147qss residues 
(M-P2, S-Pz) have also been described (13,  14). rVVs containing 
tandem T cell determinants were constructed in a manner similar 
to that described (13, 14). Briefly, synthetic oligonucleotides con- 
taining  the appropriate nucleotide  sequences  were inserted  into 
modified pSCll  or modified pSCll  containing the adenovirus 5 
E3/19K signal sequence￿9 Ligation of DNA encoding PjPz or P~PI 
into the NotI sites of the modified pSCll plasmid resulted in the 
insertion of an additional Ala between S and the first class I deter- 
minant (14). Construction of PiP2 included an initiating M codon 
(M-PIP2).  The  fidelity  of genetic  engineering  procedures  was 
confirmed by DNA sequence analysis of plasmid inserts. Genes were 
inserted into the TK locus  of VV by homologous recombination 
as described (20). 
Cytolytic Y  Cell (CTL) Assay.  Target cells (2  x  106) were in- 
fected with rVV (2  x  107 PFU) for 1 h in BSS/BSA followed by 
an additional 3-h incubation in IMDM. Cells were subsequently 
labeled  with  NaSlCrO4  (10 #Ci) for 1 h  at 37~  and were ex- 
tensively washed in IMDM. Radiolabeled target cells were suspended 
in  IMDM and incubated with  NP- or VSV-specific TcDs+ cells 
generated from splenocytes primed with rVV expressing either NP 
(originally termed V69) (21) or N  (originally termed IN N-Vac) 
(22),  and were stimulated for 7 d in vitro by autologous spleen 
cells infected with PR8 or VSV, respectively.  Effector cells were 
incubated with target cells for 6 h, after which 100/~1 culture su- 
pernatant was harvested, and the amount of released S~Cr was de- 
termined by 3' counting.  The percent-specific release  was calcu- 
lated from the formula:  [[experimental release -  spontaneous release 
(no splenocytes)]/[detergent release -  spontaneous release]l  x  100. 
Peptide Extraction.  T2 cells (109) were infected with rVV-S-PIP2 
and either VV-K  a- or VV-EClsK  a. Single  rVV infections of rVV- 
S-PiP2  and rVV-EClsK  a were controlled for by coinfection with 
wild-type VV. Cells were infected at a multiplicity of infection of 
10 for 1 h in BSS/BSA,  and were then incubated for 15 h at 37~ 
in IMEM medium supplemented with 7.5%  FBS (vol/vol). Pep- 
tides were extracted from T2 cells as described (16, 17), with the 
exception  that cellular material <3,000 kD was collected by passing 
extracts  through  filters  (Macrosep;  Filtron  Technology  Corp., 
Northborough,  MA)  (3,000 kD cut-off).  One fifth of the acid 
extract was resuspended in  H20,  vacuum dried,  resuspended in 
300/zl PBS, and assayed directly as described below. The remaining 
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Figure  1.  Trimming  of antigenic peptides in the secre- 
tory pathway. L929 (A and B) or T2 (C and D) cells were 
coinfected with rW expressing K  b or K  a, and rVV ex- 
pressing either M-P1, S-Pt, M-Pz, S-Pz, M-PIP2, S-PtP2 
or S-P2Pt. After stCr labeling, cells were incubated with 
splenocytes containing TcDs+ specific for  Pt  or  P2. 
Effector/target  ratios: Kd-restricted, P2-specific effectors 
(hatched bars) =  36.1; Kb-restricted, Pvspedfic effectors 
(solid bars)  =  12:1. 




Figure 2.  Trimming is not effected by coexpression of K ~ and K  d. T2 
target cells (A and B) were coinfected as indicated with rW expressing 
K  b or K  d or both recombinants,  and either  M-Pt, S-P1, M-P2, S-P2, 
M-PIP2, S-PIP2, or S-P2P1. After StCr or labeling, cells were incubated 
with splenocytes containing TcDs+ specific for Pt or P2. Effector/target 
ratios: Kb-restricted, Pvspecific effectors (solid bars)  +  60:1; Kd-restricted, 
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Figure 3.  Pz is  trimmed from 
S-PtP2 in the EK. (.4) stCK-labeled 
P815 (H-2  d) cells were incubated 
with threefold dilutions of TFA ex- 
tracts of material <3 kD from T2 
cells infected with rWs as indicated 
and incubated with splenocytes  con- 
taining TcDs.  specific for P2. (B) 
Material present in extracts derived 
from cells coinfected with S-PlPz 
and either  VV-K  a or VV-ECtsK  d 
was fractionated  by HPI.C and tested 
for the ability to sensitize slCr-la- 
beled P815 cells for lysis by P2-spe- 
citic TcDs+. (C) Threefold dilutions 
of peptide isolated in fraction 23 in 
B were tested for the ability to sen- 
sitize slCr-labeled  P815 cells for l~is 
by P2-specific  TCDS+. ~,  S-P1P2 
+  VV;  ~,  VV  +  EC15-Kd; 
-~-,  S-P1P2  +  EC15-Kd; --O-, 
S-P1P2  +  K  d. 
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Fractions were vacuum dried and resuspended in 300/zl PBS. NP 
peptide antigenic activity was detected in the S1Cr release assay by 
incubating threefold dilutions of each chromatographed fraction 
with 51Cr-labeled  P815 target cells preincubated overnight at 26~ 
to increase  the expression  of peptide binding MHC chss I molecules. 
Cells were labeled at 26~  with NaSlCrO4, and were incubated 
with peptide for 1 h at 26~  before the addition of H-2a-restricted, 
NP-specific splenic effector cells at an effector/target ratio of 20:1. 
Effector and target cells were incubated at 37~  for 7-8 h and har- 
vested as described above. 
Results 
Presentation of ER-targeted Tandem Peptides.  Minigenes ex- 
pressing peptide precursors of 17 residues were constructed 
from two class I-binding peptides, Ns2-s7 (P1) and NP147-15s 
(P2) arranged head-to-tail in both orientations, preceded by 
the adenovirus 5 E3/19K  signal sequence (S) as shown in 
Table 1 and as described in the Materials and Methods. rVV 
were generated to express the tandem peptides, S-P1P2, S-P2P, 
and also M-P1P2. The latter peptide lacks a signal sequence 
to control for TAP-independent peptide presentation. Since 
neither T2 cells nor L929 cells (used as TAP-expressing con- 
trol cells) express the K a or K b class I molecules that present, 
respectively,  the P1  and P2 peptides  to  TcDs+,  cells  were 
coinfected with rVVs expressing antigenic peptides and rVVs 
expressing class I a  chains. Presentation of P1 and P2 deter- 
minants was assessed in standard SlCr release assays using a 
secondary in vitro-stimulated splenocyte populations con- 
taining TcDs + specific for P1 or P2. 
As seen in Fig.  1, A  and B,  in L929 cells, both P, and 
P2 determinants were liberated from S-P,P2  and S-P2P~, as 
well as from M-P1P2. The specificity of TCDS  + recognition 
of these determinants is demonstrated by the reciprocal pat- 
tern of peptide specific lysis by TCDS+. The ability of L929 
cells to present peptides from each of the rVVs tested pro- 
vides functional demonstration of the integrity of the rVVs 
used to study presentation by T2 cells below. 
TAP-deficient T2 cells  (Fig.  1,  C  and D) demonstrated 
a more restricted pattern of presentation than L929  cells. 
Only the COOH-terminal determinant from either S-P1P2 
or S-P2P1 was presented at  similar levels to  cells  infected 
with rVVs expressing ER-inserted single determinants. Nei- 
ther peptide was presented after infection with M-P1P2 which 
demonstrates that presentation of the S-tandem peptides in 
TAP-deficient cells is signal dependent. The ability of T2 cells 
to present P1 from S-P1 and P2 from S-P2 demonstrates that 
signal peptidase is perfectly capable of cleaving each of the 
antigenic peptides from the E3/19K signal sequence in an 
antigenic form. Thus, it is very likely that each of the tandem 
peptides is liberated from the signal sequence with its NH2 
terminus intact. Most striking was the complete failure of 
T2  cells to present P2  from the S-P2P1 polypeptide.  This 
finding was consistently reproduced in a large number of 
experiments. The presentation of the P1 determinant from 
S-PIP~ peptide at intermediate levels was routinely observed, 
indicating that secretory proteases demonstrate some capacity 
to liberate this peptide from its flanking sequences. 
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Coexpression of K b and K a with precursor peptides in T2 
cells did not alter the pattern of peptide presentation, since 
cells coinfected with VV-K  d, VV-K  b, VV-S-P1,  and VV-S- 
P2  presented both  determinants  to  TcDs§ (Fig.  2).  This 
demonstrates that cells infected with even four rVVs express 
each foreign gene product at sufficient levels for TcDs + rec- 
ognition, although the decreased levels of presentation likely 
stem from reduced expression of individual gene products. 
Based on these findings, we conclude (a) that optimal pro- 
cessing of antigenic peptides from longer polypeptides within 
the secretory pathway entails that the determinant be located 
at the extreme COOH terminus; and (b) that this selective 
presentation of COOH-terminal peptides is not influenced 
by the presence or absence of a class I molecule able to bind 
the NH2-terminal peptide. 
lntmcellular  Localization of the Site of  PeFtide  Liberation.  The 
dependence  of peptide  presentation  on  a  NH2-terminal 
signal sequence demonstrates that proteolytic processing of 
the peptide occurs in the secretory pathway. To localize the 
site of proteolysis to the early (ER, c/s-Golgi  network) or 
late (medial and trans-Golgi complex, post-Golgi transport 
vesicles) portions of the secretory pathway, we used a rVV 
expressing  a  Ka-molecule  whose  cytosolic  domain  was 
replaced with  that  of the E3/19K  glycoprotein (17). We 
previously reported that L929 cells coinfected with this rVV 
(termed VV-EClsK  d) and an rVV expressing full-length NP 
do not present NP147q55 to TCDS+ (17). HPLC purification 
of TFA-soluble peptides from these cells demonstrated that 
EC1sK  a bound similar quantities of antigenic peptides as un- 
modified K a. Based on immunocytochemical and biochem- 
ical evidence,  the poor efficiency of EC15K  d presentation of 
NP147-155 can be attributed  to its retention in the ER. 
NP-specific  TcDs + were unable to lyse T2 cells coinfected 
with VV-EC,sK d and either VV S-P2 or VV S-PIPz  (not 
shown), demonstrating that EC15K  d is also retained in the 
early secretory pathway of T2 cells. To determine whether 
intracellular EC15K  d contained antigenic peptides, cells were 
homogenized in 0.1% TFA, and serial dilutions of unfrac- 
tionated material of <3 kD were tested for ability to sensi- 
tize P815 cells (H-2 d) for lysis by P2-specific TCDS  +. As seen 
in Fig.  3 A,  recovery of antigenic peptide in acid extracts 
required the coexpression S-P1P2 and EC15K  a,  once again 
demonstrating the requirement of class I molecules in the 
recovery of antigenic peptides (16). Similar amounts of pep- 
tides were recovered from cells expressing EClsK a and un- 
modified K d, indicating that retention of K d in the ER has 
little,  if any, effect on the efficiency of peptide generation 
or association.  Antigenic peptides  extracted from EClsK a 
and K a were chromatographed by reverse-phase HPLC, and 
the fractions were tested for antigenic activity. Antigenically 
active peptides were recovered in a single peak that coeluted 
with a synthetic peptide corresponding to the P2 peptide, 
NP147-155 (Fig.  3 B).  This is consistent with the possibility 
that  proteases  in  the early secretory pathway liberate the 
COOH-terminal  nonamer from S-P1P2, but  more precise 
chemical analysis of the antigenically active peptide is required 
to be certain that the peptide does not contain a few addi- 
tional NH2-terminal residues. Discussion 
In the present study, we show that proteases present in 
the early secretory pathway contribute to the processing of 
peptides delivered to the ER in a signal sequence-dependent 
manner. It is striking that the COOH-terminal peptide is 
presented much more efficiently than the NH2-terminal pep- 
tide. This cannot be attributed to chemical differences be- 
tween NH2-  and COOH-terminal peptides, since similar 
patterns were observed with rVVs encoding reciprocal pep- 
tide precursors. The more efficient presentation of the COOH- 
terminal determinant possibly reflects the critical nature of 
the interaction of COOH-terminal residues of antigenic pep- 
tides with class I molecules. The COOH-terminal residue 
serves as both an "anchor" residue whose side chain makes 
an important interaction with pockets in the class I mole- 
cule, and also provides critical binding energy through the 
interaction of main chain atoms with the binding groove. 
Extension of COOH termini by even a single residue often 
results in a drastic drop in peptide binding to class I mole- 
cules (16). We favor the idea that some portion of the tandem 
peptide is tethered to class I molecules via its COOH ter- 
minus, while the NH2-terminal portion is trimmed by an 
aminopeptidase.  The  initial  ligand  might  be  the  entire 
precursor peptide, or a fragment produced by endopeptidase 
activity. 
The presence  of endopeptidases in  the  early  secretory 
pathway is  consistent with the partial  presentation of Pl 
from S-P1P2. The  inefficient  nature  of this  presentation 
might indicate a low level of endopeptidase cleavage of the 
precise PtP2 junction, or inefficient  trimming of a longer 
peptide by carboxypeptidases.  It is important to emphasize 
that the very large difference in efficiency of presentation of 
Pl and P2 by cells expressing S-P2P1 points very strongly to- 
wards the action of an aminopeptidase that creates the Pt 
peptide from either P1P2 or a COOH-terminal fragment of 
PtP2 created by endopeptidase activity. 
Our findings implicating secretory aminopeptidases in an- 
tigen processing are, of course, limited to peptides delivered 
to the ER in a signal sequence-dependent manner. The pos- 
sibility that these proteases can also contribute to the pro- 
cessing of TAP-transported peptides is, however, supported 
by recent findings regarding the specificity of TAP. Using 
a permeabilized cell system, TAP has been directly shown 
to transport peptides of up to at least  13 residues (7). Pep- 
tides of up to 30 or so residues have been recovered from 
a subset of HLA-B27 reactive with a specific mAb. The cell 
surface binding of this mAb to TAP-deficient cells was greatly 
reduced relative to TAP-expressing cells, suggesting that TAP 
is capable of transporting even very long peptides (23). Findings 
using permeabilized cells or isolated microsomes indicate that 
TAP preferentially  transports  peptides with  the  types  of 
COOH-terminal residues favored by class I molecules (5, 6). 
Similarly, it has been reported that proteasomes (a multicata- 
lytic cytosolic protease possibly involved in antigen processing) 
preferentially produce peptides with similar COOH termini, 
while cleavage at NH2 termini is much less selective (24-26). 
These findings are consistent with the idea that many anti- 
genie peptides are delivered to the EK with the proper COOH 
terminus, but with extensions at the NH2 terminus that can 
be  removed by  ER-aminopeptidases.  Furthermore,  these 
findings imply that the presence of a carboxypeptidase in the 
early secretory pathway might constitute a serious threat to 
antigenic peptides. Notably, a deficiency in EK carboxypep- 
tidases is supported by our previous observation that expres- 
sion of an exotic secreted  carboxypeptidase is needed to facilitate 
presentation of a peptide extended by two residues from the 
natural COOH  terminus (13). 
T2 cells efficiently produce antigenic peptides from HIV-I 
gp160, probably through the action of proteases located in 
an early secretory compartment (27). The processing of in- 
tact membrane or secretory proteins in the ER of T2 cells 
would appear to be the exception rather than the rule, how- 
ever, since neither integral membrane glycoproteins from mea- 
sles (28) nor influenza viruses, nor ovalbumin, nor a secreted 
full-length form of influenza virus NP (our unpublished ob- 
servations) is detectably processed in the secretory pathway 
of these cells. Perhaps the proteolytic processing of gp160 
in T2 cells is initiated by the formation of aggregates of GP160 
with CD4, which are disposed of  by the Elk degradative system 
used to prevent the accumulation of defective proteins (29). 
It will be of interest to examine the relationship between the 
proteases that contribute to the presentation of gp160 and 
our peptide precursors. 
The identities of the secretory proteases involved in an- 
tigen processing remain to be established  by biochemical 
methods. The possible involvement of dass I molecules in 
serving as a template for the appropriate proteases, or as a 
protease itself, as suggested in explanation for the dependence 
of class I molecules on the isolation of antigenic peptides from 
cells (30), also remains as a subject of further investigation. 
The reagents described in this report should prove useful in 
the biochemical characterization of the secretory  proteases 
involved in antigen processing. 
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